Fisetin treatment (0–80 μM:24 h) to A375 and 451Lu melanoma cells resulted in a dose-dependent decrease in YB-1 phosphorylation concomitant with downregulation of total protein levels, as assessed by western blot and immunocytochemical analysis (Fig. 1A,B, Sup. Here, YBX1 is linked to melanoma.